Previous 10 | Next 10 |
Natera and Tesis Labs Announce Strategic Collaboration on Prenatal Genetic Testing PR Newswire AUSTIN, Texas , March 31, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in non-invasive genetic testing and analysis of cfDNA, a...
Natera (NTRA) has been granted two additional Breakthrough Device Designations from the FDA for its Singatera molecular residual disease test.The designations will support the development of Signatera through phase 3 trials as a companion diagnostic to two cancer therapies.Another prior ...
FDA Grants Two New Breakthrough Device Designations for Natera's Signatera™ MRD Test Designations help accelerate the regulatory review and approval of Signatera across a variety of solid tumor indications PR Newswire AUSTIN, Texas , March 24, 2021 /PR...
Natera (NTRA) announces that the first patient has been screened in a new phase III trial that uses its tumor-informed, personalized molecular residual disease ((MRD)) test, Signatera, as a companion diagnostic to identify muscle-invasive urothelial carcinoma ((MIUC)) patients eligible f...
Natera and Genentech Initiate Phase III Trial Using Signatera™ as a Companion Diagnostic for Atezolizumab in Early-Stage Muscle-Invasive Bladder Cancer Signatera used to identify muscle-invasive urothelial carcinoma patients who are MRD-positive after surgery, for enrollm...
Natera, Inc. (NTRA) Q4 2020 Earnings Conference Call February 25, 2021 04:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Matt Rabinowitz - Co-Founder & Chairman Solomon Moshkevich - General Manager of Oncology Conference Call...
The following slide deck was published by Natera, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Natera, Inc. 2020 Q4 - Results - Earnings Call Presentation
Gainers: [[GRPN]] +12.8%. [[IHRT]] +10.2%. [[ACIW]] +10.1%. [[NTRA]] +8.5%. [[ETSY]] +4%.Losers: [[TCDA]] -23.1%. [[MRIN]] -12.9%. [[TPIC]] -10%. [[TUSK]] -9.6%. [[GNMK]] -9.6%. For further details see: ETSY, GRPN, TPIC and GNMK among after-hours movers
Natera (NTRA): Q4 GAAP EPS of -$0.89 misses by $0.27.Revenue of $112.4M (+35.1% Y/Y) beats by $5.77M.Natera anticipates 2021 total revenue of $500 million to $525 million; 2021 cost of revenues to be approximately 47% to 52% of revenues; selling, general and administrative costs to be approxi...
Natera Reports Fourth Quarter and Year 2020 Financial Results PR Newswire SAN CARLOS, Calif., Feb. 25, 2021 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the fo...
News, Short Squeeze, Breakout and More Instantly...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...